The launch of the 750mcg teriparatide formulation in Australia has seen restricted availability to date. Primarily designated for patients with severe skeletal fragility who have not responded to other therapies , access is carefully managed. Existing supply amounts are limited, and individuals should confirm regarding their doctor the recent infor